On Oct 31, major Wall Street analysts update their ratings for $Incyte (INCY.US)$, with price targets ranging from $80 to $97.
Citi analyst David Lebowitz maintains with a buy rating, and adjusts the target price from $92 to $97.
TD Cowen analyst Marc Frahm maintains with a buy rating, and maintains the target price at $80.
Oppenheimer analyst Jay Olson maintains with a buy rating, and adjusts the target price from $81 to $82.
Truist Financial analyst Srikripa Devarakonda maintains with a hold rating.
JMP Securities analyst Reni Benjamin maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Incyte (INCY.US)$'s main analysts recently are as follows:
Incyte's third-quarter results showcased topline revenue surpassing expectations, fueled by the enduring growth of essential franchise components like Jakafi and Opzelura. The solid commercial performance, diminishing worries about Jakafi's rivals, and a robust pipeline with multiple opportunities reinforce the company's underlying narrative.
The firm previously held reservations about competitive pressures to Jakafi in myelofibrosis, yet acknowledges that the strong ongoing demand suggests diminished risk currently. They also note optimism driven by the sustained growth of Opzelura, including the potential for its expansion into pediatric atopic dermatitis.
The company demonstrated a robust commercial quarter, showcasing the resilience and strength of its core business despite seasonal challenges and competitive pressures. This performance is anticipated to sustain momentum and enhance investor sentiment as the company approaches several significant updates in the first half of fiscal year 2025.
The company achieved a top-line surpass and provided updated guidance for FY24 that remained steady to improved. This was despite expectations for Jakafi being counterbalanced by a reduced projection in the Heme/Oncology division. Nonetheless, the long-term prospects for the company remain uncertain, especially considering the anticipated impact on revenue from the pipeline following the Jakafi exclusivity expiration slated for 2028.
Incyte has exhibited impressive third-quarter performance, surpassing expectations with a robust top line propelled by Jakafi and Opzelura, alongside a commendable bottom line. In light of this strong commercial execution, the company has elevated its forecast for FY24, hinting at promising Q4 sales for Jakafi and a 6% year-over-year expansion for the subsequent fiscal year. It is anticipated that the industry focus will transition towards pipeline projects, as multiple imminent catalysts are on the horizon, including updates on the LIMBER program, proof of concept data for MRGPRX2 Phase 1/2 in Chronic Spontaneous Urticaria (CSU), and early-2025 top-line results from the povorcitinib Phase 3 trial in Hidradenitis Suppurativa (HS), all of which are expected to elucidate the potential for longer-term growth and compensate for the anticipated loss of exclusivity for Jakafi.
Here are the latest investment ratings and price targets for $Incyte (INCY.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$因塞特 (INCY.US)$的評級，目標價介於80美元至97美元。
花旗分析師David Lebowitz維持買入評級，並將目標價從92美元上調至97美元。
TD Cowen分析師Marc Frahm維持買入評級，維持目標價80美元。
奧本海默控股分析師Jay Olson維持買入評級，並將目標價從81美元上調至82美元。
儲億銀行分析師Srikripa Devarakonda維持持有評級。
JMP Securities分析師Reni Benjamin維持持有評級。
此外，綜合報道，$因塞特 (INCY.US)$近期主要分析師觀點如下：
因塞特第三季度的業績展示了超出預期的營收，主要得益於Jakafi和Opzelura等關鍵元件的持續增長。堅實的商業表現、對Jakafi競爭對手擔憂的減輕以及龐大的管道帶來了多重機遇，強化了公司的基礎故事。
公司此前對Jakafi在骨髄纖維化中的競爭壓力持有保留意見，但承認當前強勁的持續需求表明風險目前已減少。他們還指出，Opzelura持續增長帶來樂觀情緒，包括其擴展進入小兒特應性皮炎的潛力。
公司展示了強勁的商業季度，展示了儘管季節性挑戰和競爭壓力，核心業務仍然具有韌性和實力。預計這一表現將保持增長勢頭，並且隨着公司在2025財年上半年迎來幾個重要更新，將增強投資者情緒。
公司取得了超過預期的總體營收，併爲2024財年提供了穩健至改善的更新指引。儘管對Jakafi的預期被血液/腫瘤學部門的降低預期所抵消，公司的長期前景仍然不確定，特別是考慮到2028年Jakafi獨家使用權到期後，管道對營收的預期影響。
因塞特展現了令人印象深刻的第三季度業績，通過Jakafi和Opzelura的強勁業績超出預期，龐大的營收，以及令人欽佩的淨利潤。由於這一強勁的商業執行，公司提升了對2024財年的預測，暗示Jakafi有着有前途的第四季度銷售，以及接下來財年6%的年度擴張。行業焦點預計將轉向管道項目，因爲即將出現多重即將到來的催化劑，包括關於LIMBER計劃的更新、MRGPRX2相位1/2在慢性特發性蕁麻疹（CSU）中的概念驗證數據，以及早2025年來自相思沙他胂相3研究在腋窩慢性膿性汗腺炎（HS）的總體營收結果，所有這些都預計會闡明長期增長潛力並彌補Jakafi預計失去獨家特許權的損失。
以下爲今日5位分析師對$因塞特 (INCY.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
